- Home
- AFRM vs BBIO Comparison
AFRM vs BBIO Comparison
Compare AFRM & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AFRM | BBIO |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.3B | 12.7B |
| IPO Year | 2020 | 2019 |
Fundamental Metrics
Financial Performance| Metric | AFRM | BBIO |
|---|---|---|
| Price | $62.81 | $67.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 25 | 25 |
| Target Price | $84.52 | ★ $86.33 |
| AVG Volume (30 Days) | ★ 4.6M | 2.6M |
| Earning Date | 05-07-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 108.98 | N/A |
| EPS | ★ 0.90 | N/A |
| Revenue | ★ $3,224,412,000.00 | $502,076,000.00 |
| Revenue This Year | $30.78 | $89.45 |
| Revenue Next Year | $23.95 | $73.78 |
| P/E Ratio | $72.34 | ★ N/A |
| Revenue Growth | 38.80 | ★ 126.26 |
| 52 Week Low | $42.10 | $38.57 |
| 52 Week High | $100.00 | $84.94 |
Technical Indicators
Market Signals| Indicator | AFRM | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 44.50 | 48.84 |
| Support Level | $60.38 | $62.39 |
| Resistance Level | $70.72 | $69.85 |
| Average True Range (ATR) | 3.95 | 2.73 |
| MACD | -1.09 | 0.29 |
| Stochastic Oscillator | 5.09 | 54.55 |
Price Performance
Historical ComparisonAbout AFRM Affirm Holdings Inc.
Founded in 2012, Affirm is a market leader in the buy-now, pay-later space with around $36 billion in transaction volume in fiscal 2025. Affirm offers both zero-interest financing, which is merchant subsidized, and interest-bearing loans, which function as personal loans that are approved on a per-transaction basis. Over 70% of Affirm's transaction volume comes from its interest-bearing loans, which also comprise the majority of its revenue. Affirm operates in the United States, which accounted for more than 95% of its revenue in 2025, but the firm has also expanded to Canada and the United Kingdom.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.